Compare Deutsche Bank AG (DB) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Eli Lilly And Co — how do they compare? Deutsche Bank AG trades at $33.65 (market cap $63.13B), while Eli Lilly And Co trades at $1,166.02 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 16.8× Deutsche Bank AG's market cap, and Deutsche Bank AG pays the higher dividend (3.47%). Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and Eli Lilly And Co for 93 Days on average.
| DB | LLY | |
|---|---|---|
Market Cap | $63.13B | $1.06T |
Volume | 3,260,488 | 2,297,239 |
Sector | Financials | Health |
52-Week High | $41.56 | $1.28K |
52-Week Low | $28.37 | $799.57 |
Typical Hold Time | 80 Days | 93 Days |
Enterprise Value | $75.71B | $1.11T |
Dividend Yield | 3.47% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.63, down 4.27% amid a bearish technical signal. The stock shows attractive valuation with a P/E of 9.1 and P/B of 0.71, while recent earnings beat expectations in two of the last three quarters. Net income surged to $6.93B in 2025, though Q3 2026 investment bank revenue is expected flat to slightly down. Cash flow improved significantly with net cash flow of $7.61B in 2025.
The outlook is mixed: strong fundamentals and low valuation support upside, but bearish technicals and cautious analyst consensus (57.58% hold) indicate near-term headwinds. Key risks include revenue volatility in investment banking and macroeconomic sensitivity. The stock offers value potential if execution on 2028 targets holds.
Eli Lilly (LLY) trades at $1,169.93, up 1.07% on the day, with a bullish technical signal and strong fundamental momentum. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 exceeding the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights promising pipeline updates in weight-loss and diabetes drugs, reinforcing growth prospects.
Outlook remains favorable given dominant market position and innovation pipeline, though high valuation multiples pose a risk. Analyst consensus is strongly bullish with a $1,340 price target. Key risks include competitive pressures and execution challenges in scaling production to meet demand for blockbuster therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
